Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMTPG
Discontinued Product
0855 has been discontinued.
View all Glutamate (Metabotropic) Group II Receptors products.
Description: Group II/group III mGlu antagonist; more selective for group II than group III
Chemical Name: (RS)-α-Methyl-4-tetrazolylphenylglycine
Biological Activity for MTPG
MTPG is a group II/group III metabotropic glutamate receptor antagonist, showing selectivity for group II in electrophysiological studies.
Technical Data for MTPG
| M. Wt | 233.23 |
| Formula | C10H11N5O2 |
| Storage | Store at RT |
| CAS Number | 169209-66-9 |
| PubChem ID | 1212 |
| InChI Key | OZBFBAYESADVDX-UHFFFAOYSA-N |
| Smiles | CC(N)(C(O)=O)C1=CC=C(C=C1)C1=NN=NN1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for MTPG
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for MTPG
References are publications that support the biological activity of the product.
Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71 PMID: 8864696
Bushell et al (1996) Pharmacological antagonism of the actions of group II and group III mGluR agonists in the lateral perforant path of rat hippocampal slices. Br.J.Pharmacol. 117 1457 PMID: 8730739
Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851 PMID: 8532166
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group II Receptor Antagonists
Keywords: MTPG, MTPG supplier, Group, II, group, III, mGlur, antagonists, selective, Receptors, mGlu2, mGlu3, mGluR3, mGluR2, Glutamate, Metabotropic, (Metabotropic), 0855, Tocris Bioscience
Citations for MTPG
Citations are publications that use Tocris products.
Currently there are no citations for MTPG.
Reviews for MTPG
There are currently no reviews for this product. Be the first to review MTPG and earn rewards!
Have you used MTPG?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.